Clinical trial
Study of Intra-articular Delivery of tgAAC94 in Inflammatory Arthritis Subjects
NCT00126724 · Targeted Genetics Corporation, Industry · Completed
Key facts
| NCT number | NCT00126724 |
|---|---|
| Title | Study of Intra-articular Delivery of tgAAC94 in Inflammatory Arthritis Subjects |
| Official title | A Phase I/II Study of Repeat Intra-articular Administration of tgAAC94, a Recombinant Adeno-Associated Vector Containing the TNFR:Fc Fusion Gene, in Inflammatory Arthritis Subjects With and Without Concurrent TNF-alpha Antagonists |
| Lead sponsor | Targeted Genetics Corporation, Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Arthritis, Rheumatoid, Psoriatic, Ankylosing Spondylitis |
| Intervention type | Genetic |
| Interventions | tgAAC94 gene therapy vector, tgAAC94 placebo |
| Enrollment | 120 |
| Start date | Aug 1, 2005 |
| Primary completion | Oct 1, 2008 |
| Completion | May 1, 2009 |
| First posted | Aug 4, 2005 |
| Last update posted | Jul 29, 2009 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: